Research ExplorerPublicationsCross-Variant Neutralizing Serum Activity after SARS-CoV-2 B...

Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections

Standard

Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. / Tober-Lau, Pinkus; Gruell, Henning; Vanshylla, Kanika; Koch, Willi M; Hillus, David; Schommers, Philipp; Suárez, Isabelle; Suttorp, Norbert; Sander, Leif Erik; Klein, Florian; Kurth, Florian.

In: EMERG INFECT DIS, Vol. 28, No. 5, 05.2022, p. 1050-1052.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Tober-Lau, P, Gruell, H, Vanshylla, K, Koch, WM, Hillus, D, Schommers, P, Suárez, I, Suttorp, N, Sander, LE, Klein, F & Kurth, F 2022, 'Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections', EMERG INFECT DIS, vol. 28, no. 5, pp. 1050-1052. https://doi.org/10.3201/eid2805.220271

APA

Tober-Lau, P., Gruell, H., Vanshylla, K., Koch, W. M., Hillus, D., Schommers, P., Suárez, I., Suttorp, N., Sander, L. E., Klein, F., & Kurth, F. (2022). Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. EMERG INFECT DIS, 28(5), 1050-1052. https://doi.org/10.3201/eid2805.220271

Vancouver

Tober-Lau P, Gruell H, Vanshylla K, Koch WM, Hillus D, Schommers P et al. Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. EMERG INFECT DIS. 2022 May;28(5):1050-1052. https://doi.org/10.3201/eid2805.220271

Bibtex

@article{c2d48ceace43426aa05c796e1ed040d6,
title = "Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections",
abstract = "To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers.",
keywords = "Antibodies, Neutralizing, Antibodies, Viral, COVID-19, Humans, SARS-CoV-2, Vaccination",
author = "Pinkus Tober-Lau and Henning Gruell and Kanika Vanshylla and Koch, {Willi M} and David Hillus and Philipp Schommers and Isabelle Su{\'a}rez and Norbert Suttorp and Sander, {Leif Erik} and Florian Klein and Florian Kurth",
year = "2022",
month = may,
doi = "10.3201/eid2805.220271",
language = "English",
volume = "28",
pages = "1050--1052",
journal = "EMERG INFECT DIS",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "5",

}

RIS

TY - JOUR

T1 - Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections

AU - Tober-Lau, Pinkus

AU - Gruell, Henning

AU - Vanshylla, Kanika

AU - Koch, Willi M

AU - Hillus, David

AU - Schommers, Philipp

AU - Suárez, Isabelle

AU - Suttorp, Norbert

AU - Sander, Leif Erik

AU - Klein, Florian

AU - Kurth, Florian

PY - 2022/5

Y1 - 2022/5

N2 - To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers.

AB - To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers.

KW - Antibodies, Neutralizing

KW - Antibodies, Viral

KW - COVID-19

KW - Humans

KW - SARS-CoV-2

KW - Vaccination

U2 - 10.3201/eid2805.220271

DO - 10.3201/eid2805.220271

M3 - Other (editorial matter etc.)

C2 - 35259088

VL - 28

SP - 1050

EP - 1052

JO - EMERG INFECT DIS

JF - EMERG INFECT DIS

SN - 1080-6040

IS - 5

ER -